What Can You Expect in 2027?
Three specialist communities. One integrated summit.
For 2027, the 6th mRNA-Based Therapeutics & Non-Viral Delivery Summit Europe marks an exciting new chapter, uniting mRNA therapeutic development, non-viral delivery and process development & CMC in one expanded European meeting. For the first time, connect with experts across the entire mRNA development pathway, explore how advances in RNA design, LNP delivery and manufacturing influence one another, and gain the cross-functional insights needed to move promising RNA medicines towards the clinic.
Across two dedicated tracks covering R&D & Preclinical Development and Process Development & CMC, hear new data and practical insights into improving extrahepatic RNA delivery, achieving productive endosomal release, extending therapeutic protein expression and matching RNA modalities to clinical needs. Explore emerging applications in oncology, rare and genetic diseases, respiratory conditions and in vivo cell engineering, alongside advances in targeted LNPs, alternative non-viral carriers, circRNA and long-acting RNA technologies.
Beyond therapeutic design and delivery, benchmark strategies for removing impurities without compromising RNA recovery, preserving mRNA-LNP quality during downstream processing, and developing potency assays that demonstrate biological function. With insights from AstraZeneca, BioNTech, Sanofi, Abogen, Circurna, Altamira Therapeutics and more, connect with the R&D, delivery, analytical and CMC specialists tackling these challenges to make better-informed development decisions, identify relevant technology partners and progress RNA therapeutics towards clinical development.
What's New for 2027?
Beyond Conventional mRNA: Engineering Expression for Therapeutic Need
Moving beyond short-term protein expression requires RNA formats that match the dosing needs of chronic disease. Examine long-acting xRNA, circRNA and non-viral genome engineering approaches designed to extend therapeutic activity without frequent administration.
Hear from:
Ohad Yogev, Vice President, Discovery, ScionxBio
Eoghan O’Leary, Vice President, Research, Circio
Matthias Bozza, Vice President, Strategy & Development, CPTx
Beyond the Liver: Advancing Tissue- & Cell-Specific RNA Delivery
Extrahepatic delivery remains a major limitation for RNA therapeutics. Discover how ligand-functionalised LNPs, modular peptide nanoparticles and cell-penetrating systems are being engineered to improve tissue selectivity, intracellular release and therapeutic performance.
Hear from:
Sara Carvalho, Founding Scientist, NanoGrab
Covadonga Pañeda, Chief Operating Officer, Altamira Therapeutics
Ana Rebane, Professor of Molecular Medicine, University of Tartu
From RNA Purification to GMP: Making Emerging Modalities Manufacturable
Scaling RNA manufacturing demands more than increasing batch size. Compare strategies to remove dsRNA, improve circRNA recovery without RNase R, preserve LNP quality during downstream processing and define analytical assays that reflect therapeutic function.
Hear from:
Peter Weinstein, Chief Executive Officer, Circurna
Constanze Ochmann-Harding, Director CMC, Epitopea
Abhi Kavathia, Associate Director GMP/CMC Drug Product, BioNTech SE
AI & Automation: Accelerating RNA and Delivery Platform Development
Traditional screening and development workflows can limit how quickly RNA candidates and ionisable lipids are evaluated. Explore AI-guided lipid screening, automated DNA-to-mRNA workflows and data-driven optimisation of therapeutic platforms to improve selection and reduce development timelines.
Hear from:
Pengbo Guo, Head of Product Development, CybernaX Bio
Sergio Linares Fernández, Unit Head, mRNA Science Automation, Sanofi
Bo Ying, Chief Executive Officer, Abogen
Two Specialist Tracks. One Connected Development Journey.
From engineering RNA for therapeutic performance to developing robust mRNA-LNP products for clinical manufacturing, the 2027 programme brings together the expertise needed across the development pathway. Dive into dedicated scientific sessions within each track, while shared plenaries connect the decisions that influence RNA design, delivery and manufacturability.
R&D & Preclinical Development
From RNA Engineering to Therapeutic Performance
Explore how RNA modality, expression duration and delivery route influence therapeutic outcomes. Examine long-acting RNA for reduced dosing frequency, targeted LNPs for extrahepatic delivery and non-viral nucleic acid delivery for in vivo cell engineering.
Sessions Not to Miss
Long-Acting xRNA for Durable Combination Peptide Therapy
ScionxBio
Advancing In Vivo CAR-T Through Non-Viral DNA & mRNA Co-Delivery
CPTx
Developing Cell-Specific LNPs Using Targeting Ligands
NanoGrab
Also featuring AstraZeneca, Altamira Therapeutics, Circio and University of Tartu.
Process Development & CMC
From RNA Synthesis to GMP-Ready Drug Products
Address dsRNA removal, circRNA recovery and RNA-LNP product quality without compromising yield or biological activity. Compare phase-appropriate CMC strategies, potency assays linked to biological function and scalable post-formulation processing.
Sessions Not to Miss
Reducing circRNA Manufacturing Costs Through Enzyme-Free Purification
Circurna
Developing Potency Assays That Connect Product Quality to Biological Function
Epitopea
Adapting CMC & Quality by Design for Individualised mRNA-LNP Therapies
BioNTech
Also featuring Fraunhofer IMM, National Taiwan University, Sanofi and University of Sheffield.
Explore the Full Event Guide
Discover what's bringing Europe's RNA therapeutics, non-viral delivery and CMC communities together in Berlin.
- 28+ Expert Speakers
Hear from AstraZeneca, BioNTech, Sanofi, Abogen and emerging RNA innovators - 2 Specialist Content Streams
Dive into R&D & Preclinical Development or Process Development & CMC, with shared plenaries bridging both - 3 Established Conferences United
Connecting mRNA therapeutics, lipid nanoparticle development and mRNA manufacturing in one summit - 6+ Therapeutic Areas Explored
From oncology and genetic diseases to respiratory, cardiometabolic, autoimmune and ocular applications
Attending Companies Include
Explore the Agenda
Discover the latest advances in RNA therapeutics, targeted non-viral delivery and mRNA manufacturing, from tissue-specific LNPs and emerging RNA modalities to GMP-ready processes.
Partner With Us
Showcase your RNA technologies, delivery platforms and manufacturing solutions to biopharma decision-makers seeking partners to overcome critical development challenges.
Join Biopharma Experts
Connect with Europe's therapeutic R&D, non-viral delivery and CMC experts in one integrated summit, bringing together the teams advancing next-generation mRNA medicines towards the clinic.